Kiora Pharmaceuticals Inc financial data

Symbol
KPRX on Nasdaq, KPHMW on OTC
Industry
Pharmaceutical Preparations
Location
332 Encinitas Boulevard, Suite 102, Encinitas, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
EYEGATE PHARMACEUTICALS INC (to 11/4/2021)
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 991 % +192%
Debt-to-equity 27.8 % -62.2%
Return On Assets 9.09 %
Operating Margin 28.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3M shares -88.6%
Common Stock, Shares, Outstanding 3M shares +250%
Entity Public Float 12.2M USD +157%
Common Stock, Value, Issued 268K USD +247%
Weighted Average Number of Shares Outstanding, Basic 3.87M shares +620%
Weighted Average Number of Shares Outstanding, Diluted 4.13M shares +667%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 16M USD
Research and Development Expense 7.84M USD +94.7%
General and Administrative Expense 5.54M USD +18.9%
Operating Income (Loss) 4.51M USD -21.1%
Nonoperating Income (Expense) 1.15M USD +604%
Net Income (Loss) Attributable to Parent 3.59M USD -86.2%
Earnings Per Share, Basic 0.93 USD/shares
Earnings Per Share, Diluted 0.87 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.79M USD +54.5%
Accounts Receivable, after Allowance for Credit Loss, Current 601K USD
Assets, Current 29.7M USD +527%
Property, Plant and Equipment, Net 5.23K USD -35.1%
Operating Lease, Right-of-Use Asset 57.2K USD -46.5%
Intangible Assets, Net (Excluding Goodwill) 6.69M USD -24.1%
Other Assets, Noncurrent 24.9K USD -38.9%
Assets 36.5M USD +166%
Accounts Payable, Current 416K USD +101%
Employee-related Liabilities, Current 1.17M USD +33.6%
Accrued Liabilities, Current 4.59M USD +232%
Liabilities, Current 6.01M USD +268%
Deferred Income Tax Liabilities, Net 491K USD -37%
Operating Lease, Liability, Noncurrent 33.8K USD -43.5%
Liabilities 10.7M USD +41.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -282K USD -54.4%
Retained Earnings (Accumulated Deficit) -143M USD +2.45%
Stockholders' Equity Attributable to Parent 25.8M USD +322%
Liabilities and Equity 36.5M USD +166%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 13.6M USD
Net Cash Provided by (Used in) Financing Activities 15.2M USD +2871%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 150M shares +200%
Common Stock, Shares, Issued 3M shares +250%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 28.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.8M USD +54.4%
Deferred Tax Assets, Valuation Allowance 13.1M USD -60.2%
Deferred Tax Assets, Gross 14.3M USD -58.5%
Operating Lease, Liability 57.2K USD -46.5%
Lessee, Operating Lease, Liability, to be Paid 82K USD +338%
Property, Plant and Equipment, Gross 6.26K USD -56.4%
Operating Lease, Liability, Current 23.4K USD -50.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 14.6K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 27.8K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.42K USD -49.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 14.6K USD
Deferred Tax Assets, Operating Loss Carryforwards 9.24M USD -64.4%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.5K USD
Additional Paid in Capital 169M USD +10.4%
Depreciation, Depletion and Amortization 4.87K USD -51.7%
Deferred Tax Assets, Net of Valuation Allowance 1.2M USD -20.6%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%